RootPath, a Cambridge, MA-based biotechnology company developing a personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy, raised $7m in seed funding.
The round was led by Sequoia China with participation from Volcanics Venture, BV (Baidu Ventures) and Nest.Bio Ventures.
The company will use its proceeds to advance its immuno-oncology programs and obtain key data on accuracy, efficacy and safety in animal models.
Founded in 2017 by Drs. Xi Chen, Le Cong, Yinqing Li and Ely Porter, RootPath develops a personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. It is developing next generation technologies to precisely monitor, modulate and steer the immune system to innovate the fields of the diagnosis and treatment of cancer.
The company was launched by Nest.Bio Ventures in 2017 and was incubated in Nest.Bio Labs in both Cambridge, Massachusetts and Hangzhou, China.